Open AccessThe T-Cell Response to SARS-CoV-2 Vaccination in Inflammatory Bowel Disease is Augmented with Anti-TNF Therapy
Author(s) -
Dalin Li,
Alexander M. Xu,
Emebet Mengesha,
Rebecca Elyanow,
Rachel Gittelman,
Heidi Chapman,
John Prostko,
Edwin C. Frias,
James L. Stewart,
Valeriya Pozdnyakova,
Philip Debbas,
Angela Mujukian,
Arash Horizon,
Noah Merin,
Sandy Joung,
Gregory J. Botwin,
Kimia Sobhani,
Jane C. Figueiredo,
Susan Cheng,
Ian M. Kaplan,
Dermot McGovern,
Akil Merchant,
Gil Y. Melmed,
Jonathan Braun
Publication year - 2022
Publication title -
inflammatory bowel diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.932
H-Index - 146
eISSN - 1536-4844
pISSN - 1078-0998
DOI - 10.1093/ibd/izac071
Subject(s) - medicine , inflammatory bowel disease , tumor necrosis factor alpha , immunology , vaccination , antibody , immune system , antibody response , disease
Lay Summary T-cell and antibody responses to severe acute respiratory syndrome coronavirus 2 vaccination in inflammatory bowel disease patients are poorly correlated. T-cell responses are preserved by most biologic therapies, but augmented by anti-tumor necrosis factor (anti-TNF) treatment. While anti-TNF therapy blunts the antibody response, cellular immunity after vaccination is robust.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom